Patents by Inventor Yoshiko Iwai

Yoshiko Iwai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200284792
    Abstract: The present invention aims to develop a method capable of evaluating T cell immune function. A method for evaluating T cell immune function including detecting and quantifying soluble PD-L1 having a binding ability to PD-1, and an ELISA system used for detecting and quantifying bsPD-L1, including a carrier with a solid-phased PD-1 protein, a means for reacting the carrier and a test sample, and a means for detecting and m quantifying soluble PD-L1 bound to the carrier as bsPD-L1.
    Type: Application
    Filed: September 7, 2018
    Publication date: September 10, 2020
    Applicants: UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN, NIPPON MEDICAL SCHOOL FOUNDATION
    Inventors: Yoshiko IWAI, Masahiro TAKEUCHI, Tomomitsu DOI
  • Publication number: 20200062846
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Application
    Filed: July 1, 2019
    Publication date: February 27, 2020
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
  • Publication number: 20170051060
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Application
    Filed: August 2, 2016
    Publication date: February 23, 2017
    Applicants: ONO PHARMACEUTICAL CO., LTD
    Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
  • Patent number: 9439962
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: September 13, 2016
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Patent number: 9402899
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: August 2, 2016
    Assignees: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Patent number: 9393301
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1 PD-L2 are useful for cancer or infection treatment.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: July 19, 2016
    Assignees: ONO PHARMACEUTICAL CO., LTD., TASUKU HONJO
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Publication number: 20160158355
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Application
    Filed: January 19, 2016
    Publication date: June 9, 2016
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
  • Publication number: 20160158356
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.
    Type: Application
    Filed: January 19, 2016
    Publication date: June 9, 2016
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
  • Publication number: 20150197572
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Application
    Filed: March 4, 2015
    Publication date: July 16, 2015
    Applicants: Ono Pharmaceutical Co., LTD., Tasuku HONJO
    Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
  • Patent number: 9073994
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 7, 2015
    Assignees: Ono Pharmaceutical Co., LTD.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Patent number: 9067999
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: June 30, 2015
    Assignees: Ono Pharmaceutical Co., LTD.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Publication number: 20150093380
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Application
    Filed: November 21, 2014
    Publication date: April 2, 2015
    Inventors: Tasuku HONJO, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Publication number: 20140314714
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 23, 2014
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
  • Patent number: 8728474
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: May 20, 2014
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Patent number: 8168179
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: May 1, 2012
    Assignees: ONO Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Publication number: 20110081341
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Application
    Filed: December 2, 2010
    Publication date: April 7, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD., Tasuku HONJO
    Inventors: Tasuku HONJO, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Publication number: 20090297518
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Application
    Filed: August 10, 2009
    Publication date: December 3, 2009
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Patent number: 7595048
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of the immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibit the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: September 29, 2009
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Publication number: 20060110383
    Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
    Type: Application
    Filed: July 2, 2003
    Publication date: May 25, 2006
    Inventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
  • Publication number: 20040253556
    Abstract: A silver halide light-sensitive color photographic material comprising a substrate having thereon layers which include a light-sensitive layer, wherein the light-sensitive layer contains a compound which is capable of producing a chemically inert and a colorless compound by chemically bonding with an aromatic amine color development agent which remains in the light-sensitive layer after the color photographic material has been subjected to color development using a development solution which contains the development agent, a total amount of a hydrophilic binder contained in the layers which are provided on the silver halide emulsion layer side of the substrate is less than or equal to 6.3 g/m2, and a total thickness of all the layers is less than or equal to 7.0 &mgr;m.
    Type: Application
    Filed: June 2, 2004
    Publication date: December 16, 2004
    Applicant: Konica Minolta Photo Imaging, Inc
    Inventor: Yoshiko Iwai